Cat. No.: HY-N0159

Paeonol

12 Cited Publications

Avis client

Based on 12 publication(s) in Google Scholar

Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC₅₀ of 54.6 μM and 42.5 μM, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 552-41-0
Formule: C₉H₁₀O₃
Masse moléculaire:166.18

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Paeonol Chemical Structure

CAS No.: 552-41-0

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits MAO-A and MAO-B with IC₅₀ of 54.6 μM and 42.5 μM, respectively.

IC₅₀ & Target

IC50: 42.5 μM (MAO-B), 54.6 μM (MAO-A)^[1]

Voir tous les produits spécifiques à Isoform Monoamine Oxidase :

MAO-A
MAO-B

Cellular Effect

Cell Line	Type	Value	Description	References
Ventricular myocyte	IC₅₀	561 μM Compound: Paeonol	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Paeonol is found to be inhibitory against MAO A in a dose-dependent manner with IC₅₀ value of 54.6 μM. Paeonol is shown to inhibit MAO-B in a dose-dependent manner with the IC₅₀ of 42.5 μM. For Paeonol, the K_i is estimated to be 51.1 μM. The inhibition of Paeonol on MAO B is of competitive type with K_i value of 38.2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The 200 mg/kg Paeonol+I/R group [AN/V (%): 7.6±2.2, p<0.01] and 100 mg/kg Paeonol+I/R group [AN/V (%): 9.4±2.8, p<0.05] both show lesser extents of no-reflow area in the ventricles compared with the I/R group [AN/V (%): 18.2±2.9]. In particular, the 200 mg/kg Paeonol + I/R group experienced markedly alleviated no-reflow in the whole heart [AN/WH (%): 4.6±1, p<0.05] compared with the I/R group [AN/WH (%): 10.0±1.9]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 552-41-0
Appearance Solid
Masse moléculaire 166.18
Formule C₉H₁₀O₃
Color White to off-white
SMILES

CC(C1=CC=C(OC)C=C1O)=O
Structure Classification
- Phenols
- Monophenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All Histological Imaging/StainingFlow CytometryWBIF

Sort by:

Journal Impact Factor

Phytomedicine

Paeonol alleviates pulmonary arterial hypertension by activation of BRCC3. [Abstract]

2026 Mar:152:157888. PMID: 41638058

Paeonol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Mar:152:157888. [Abstract]

Paeonol (PAE) inhibits pulmonary vascular remodeling. Representative images of pulmonary artery hematoxylin-eosin (H&E) staining and quantitative analysis of pulmonary artery (PA) wall thickness.

Paeonol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Mar:152:157888. [Abstract]

Paeonol (PAE: 50 μM) inhibited the proliferation of pulmonary artery smooth muscle cells and promoted their apoptosis. The proportion of apoptotic cells was determined by flow cytometry.

Paeonol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Mar:152:157888. [Abstract]

Paeonol (PAE: 50 μM). Western blotting analysis of Bcl-XL, Bid, BAX, cleaved Caspase-3 (cle-Casp3) and β-actin.

Paeonol purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Mar:152:157888. [Abstract]

Paeonol (PAE: 50 μM) enhances the BMPR2-Smad1/5 signaling pathway and attenuates the TGF-β/Smad2/3 signaling pathway by activating BRCC3. Immunofluorescence staining showed intranuclear (DAPI, blue) translocation of Smad3 (red) in PASMCs under different treatment conditions (n = 3).
Cell Rep

Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity. [Abstract]

2025 Apr 16;44(5):115572. PMID: 40249703
Int Immunopharmacol

Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment. [Abstract]

2026 May 1:176:116468. PMID: 41819671
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Metabolites

Paeonol Ameliorates Ulcerative Colitis in Mice by Modulating the Gut Microbiota and Metabolites. [Abstract]

2022 Oct 8;12(10):956. PMID: 36295858
Exp Cell Res

The effect of TSPO transmembrane transport-mediated paeonol mitochondrial antioxidant on dexamethasone-induced mitochondrial abnormalities, oxidative stress damage, and apoptosis in SV40-MES-13 cells. [Abstract]

2025 Jul 15;450(2):114674. PMID: 40683587
J Inorg Biochem

Paeonol protects renal tubular cells against cadmium-induced cytotoxicity via alleviating oxidative stress, inhibiting inflammatory responses and restoring autophagy. [Abstract]

2022 May:230:111733. PMID: 35131642
Pharmacol Res Perspect

Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells. [Abstract]

2026 Feb;14(1):e70213. PMID: 41445272
Exp Ther Med

Paeonol suppresses lipid formation and promotes lipid degradation in adipocytes. [Abstract]

2022 Jan;23(1):78. PMID: 34938364
Oncol Lett

Therapeutic effects of paeonol on non‑small cell lung cancer cells via regulation of the MAPK pathway. [Abstract]

2024 Sep 24;28(6):560. PMID: 39372664
Biochem Biophys Res Commun

Paeonol protects against acute pancreatitis by inhibiting M1 macrophage polarization via the NLRP3 inflammasomes pathway. [Abstract]

2022 Apr 16:600:35-43. PMID: 35182973
Int J Ophthalmol

Paeonol suppresses epithelial-mesenchymal transition-driven posterior capsular opacification through activation of AMPK signaling. [Abstract]

2026 Feb 18;19(2):219-229. PMID: 41573007

Solvant et solubilité

In Vitro:

Ethanol : 50 mg/mL (300.88 mM; Need ultrasonic)

DMSO : ≥ 38 mg/mL (228.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.0176 mL

30.0879 mL

60.1757 mL

5 mM

1.2035 mL

6.0176 mL

12.0351 mL

10 mM

0.6018 mL

3.0088 mL

6.0176 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (15.04 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[2]

Mice^[2]
Male Wistar rats (180-220 g, average age of 8 week) are randomly divided into four groups: (1) sham group, thoracotomy without left anterior descending coronary artery (LAD) occlusion or Paeonol pretreatment; (2) I/R group, LAD occlusion (ischemia) for 4 h followed by reperfusion for 8 h; (3) Paeonol (100 mg/kg)+I/R group, oral administration of 100 mg/kg Paeonol (1 mL/kg) for 7 days using a intragastric tube prior to I/R procedure; (4) Paeonol (200 mg/kg) + I/R group, oral administration of 200 mg/kg Paeonol (1 mL/kg) for 7 days using a intragastric tube prior to I/R procedure. In addition, rats in the sham and I/R groups received a dosage of DMSO equal to that with which the Paeonol was dissolved in for the other two groups. DMSO was also administered intragastrically for 7 consecutive days. A minimum of eight rats were assigned to each group. An ischemia group without reperfusion is not included since our present study mainly focuses on the effect of Paeonol on the cardiac injuries after reperfusion, which is closely related to the real-world situation of no-reflow after coronary revascularization. However, future studies may include a group subjected only to 4 h of ischemia to differentiate, in terms of damage to the cardiac function, which was due to the ischemia and which was due to the no-reflow.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kong LD, et al. Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol. 2004 Apr;91(2-3):351-5. [Content Brief]

[2]. Ma L, et al. Paeonol Protects Rat Heart by Improving Regional Blood Perfusion during No-Reflow. Front Physiol. 2016 Jul 21;7:298. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	6.0176 mL	30.0879 mL	60.1757 mL	150.4393 mL
	5 mM	1.2035 mL	6.0176 mL	12.0351 mL	30.0879 mL
	10 mM	0.6018 mL	3.0088 mL	6.0176 mL	15.0439 mL
	15 mM	0.4012 mL	2.0059 mL	4.0117 mL	10.0293 mL
	20 mM	0.3009 mL	1.5044 mL	3.0088 mL	7.5220 mL
	25 mM	0.2407 mL	1.2035 mL	2.4070 mL	6.0176 mL
	30 mM	0.2006 mL	1.0029 mL	2.0059 mL	5.0146 mL
	40 mM	0.1504 mL	0.7522 mL	1.5044 mL	3.7610 mL
	50 mM	0.1204 mL	0.6018 mL	1.2035 mL	3.0088 mL
	60 mM	0.1003 mL	0.5015 mL	1.0029 mL	2.5073 mL
	80 mM	0.0752 mL	0.3761 mL	0.7522 mL	1.8805 mL
	100 mM	0.0602 mL	0.3009 mL	0.6018 mL	1.5044 mL

Keywords

Paeonol

12 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Paeonol

Neuronal Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Paeonol

Voir tous les produits spécifiques à Isoform Monoamine Oxidase

Activité biologique

Chemical Information

Publications (12)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Paeonol Related Classifications

Cat. No.: HY-N0159